An anonymous director reports

RAKOVINA THERAPEUTICS ANNOUNCES EXTENSION OF NON-BROKERED PRIVATE PLACEMENT

The TSX Venture Exchange has granted Rakovina Therapeutics Inc. a 30-day extension with respect to its non-brokered private placement financing, previously announced on Jan. 27, 2026, and Feb. 20, 2026. The offering is now expected to close on or before April 9, 2026, or other such date or dates as determined by the company and acceptable to the TSX-V.

As previously disclosed, the company intends to raise up to $1-million through the offering as follows.

The offering will comprise up to 8,333,334 common shares at a price of 12 cents per share for gross proceeds of up to approximately $1-million. As consideration for services provided in connection with the common share private placement, the company may pay finders' fees to certain eligible finders that introduce subscribers to the financing.

The company intends to use the net proceeds of the offering to provide near-term working capital to support continuing corporate activities and strategic initiatives while the company continues to evaluate longer-term financing alternatives.

About Rakovina Therapeutics Inc.

Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. The company's work is based on unique technologies for targeting the DNA-damage response powered by artificial intelligence (AI) using validated, proprietary platforms. By using AI, the company can review and optimize drug candidates at a much greater pace than ever before.

The company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners.

We seek Safe Harbor.